Illicit
Drug Monitoring System (IDMS)
The Illicit
Drug Monitoring System (IDMS) was established in 2005 to provide ongoing and timely information on changes in drug
use and drug related harm in New Zealand. It is conducted
annually as part of the National Drug Policy. The data collected
in the IDMS is intended to be used by a wide range of people
and organisations to inform appropriate and timely responses
to drug use in New Zealand. The research protocols used in
the IDMS have been approved by the Massey University Human
Subjects Ethics Committee.
2008 IDMS - findings released 11 June 2009
The 2008 Illicit Drug Monitoring System (IDMS) report presents findings from the 2008 IDMS and compares the 2008 findings to the 2007 and 2006 IDMS findings. The 2008 IDMS interviewed 404 frequent drug users, (up from the 324 interviewed in 2007) in Auckland, Wellington and Christchurch using purposive sampling and snowballing. The 2008 IDMS sample included 137 frequent methamphetamine users, 135 frequent ecstasy (MDMA) users and 132 frequent injecting drug users. The interviews with frequent drug users were contextualised with secondary data sources of drug use, such as drug seizure statistics, calls to the Alcohol and Drug Helpline, admissions to CADS drug treatment services and National Household Drug Survey data. The project report and Executive Summary can be downloaded below:
RECENT TRENDS IN ILLEGAL
DRUG USE IN
NEW ZEALAND, 2006-2008
Findings from the 2006, 2007 and
2008 Illicit Drug Monitoring System
(IDMS) (full report) and Executive Summary
2007 IDMS - findings released 14 July 2008
The 2007 IDMS interviewed 324 frequent drug users, (similar to the 318 interviewed in 2006) in Auckland, Wellington and Christchurch using purposive sampling and snowballing. The 2007 IDMS sample included 110 frequent methamphetamine users, 105 frequent ecstasy (MDMA) users and 109 frequent injecting drug users. The interviews with frequent drug users were contextualised with information provided by key experts working in the drugs field, and with secondary data sources of drug use, such as drug seizure statistics and national household drug survey data. The project reports and a research briefing can be downloaded below.
IDMS Research Briefing 01/07 February 2009
Drug-related harm among younger and older frequent methamphetamine users in
New Zealand: Findings from the 2006 and 2007 Illicit Drug Monitoring System (IDMS)
Recent Trends in Illegal Drug use in New Zealand, 2005-2007: Findings from the 2005, 2006 and 2007 Illicit Drug Monitoring System (IDMS)
Trends in Drug Use in Auckland, Wellington and Christchurch: Findings from the three site locations of the 2006 and 2007 Illicit Drug Monitoring System (IDMS)
Recent Trends in Illegal Drug markets in New Zealand, 2005-2007: Findings from the 2005, 2006 and 2007 Illicit Drug Monitoring System (IDMS)
2006 IDMS
The 2006 IDMS interviewed 318 frequent drug users,
(up from 181 interviews in 2005) in Auckland, Wellington and
Christchurch using purposive sampling and snowballing. The
2006 IDMS sample included 114 frequent methamphetamine users,
111 frequent ecstasy (MDMA) users and 93 frequent injecting
drug users. The interviews with frequent drug users were contextualised
with information provided by key experts working in the drugs
field, and with secondary data sources of drug use, such as
drug seizure statistics and national household drug survey
data. The main project report and two research briefings summarising
the findings can be downloaded below.
2006
Main IDMS report
Research
Bulletin 1 - Trends in Drug Use
Research
Bulletin 2 - Trends in Drug Related Harm
Research
Bulletin 3 - Frequent injecting drug use
2005 IDMS
The
2005 IDMS consisted of three modules based on the type of
frequent illicit drug user interviewed: (i) the Methamphetamine
Module, which interviewed frequent methamphetamine users;
(ii) the Hallucinogen Module, which interviewed frequent ecstasy
(MDMA) and LSD users; and (iii) the Cannabis Module, which
interviewed frequent cannabis users.
The
research briefings below summarise the key findings from each
of the modules and from the combined samples of the three
modules.
Combined Sample Briefing |
Methamphetamine Module Briefing |
Cannabis Module Briefing |
Hallucinogen Module Briefing |
The detailed findings for each of the three modules are presented
in larger separate reports:
Methamphetamine
Module Report
Cannabis Module Report
Hallucinogen
Module Report
Back
|
